DEDHAM, MA, JULY 27, 2009 - Slingshot Software today announced the addition of Craig Armstrong, Vice President International of LoJack Corporation, and Dan Powdermaker, Sr. Vice President Sales and Marketing at Arbinet, to its Board of Directors.
DEDHAM, MA, JULY 27, 2009 - Slingshot Software today announced the addition of Craig Armstrong, Vice President International of LoJack Corporation, and Dan Powdermaker, Sr. Vice President Sales and Marketing at Arbinet, to its Board of Directors.
Investing in the future of your business during periods of economic uncertainty is what separates your business from the competition. Industry leaders confirm that now is a good time to make strategic investments in your company’s operational systems. ERP software should be on top of your to-do list, given the positive impact that improvements in procurement and supply chain management can have on your bottom line.
For some time now, statistics have shown a steady increase in the Food and Drug Administration's (FDAs) monitoring of pharmaceutical companies' compliance with 21 CFR Part 11 and other regulations.
This article in the New York Times makes reference to this, and the Federal Government's increasing focus (through the Government Accountability Office) on the safety of all pharmaceutical products (both equipment and medicines) on the market.
The article highlights a situation where the Federal Government is now insisting on retro-active compliance of medical devices that pre-date the enactment of medical device law in 1976. This kind of scrutiny from all regulatory bodies can be expected to increase over time.
The issue of Combination Devices is a particularly important one right now as the charter of a number of separate FDA departments have been combined to make sure that compliance regulations are properly maintained and monitored.
Slingshot Software is pleased to announce that it will be hosting a free Webinar that is all about using technology to turn your compliance against 21 CFR Part 11 - and other regulations - into an undeniable competitive advantage.

What is Title 21 CFR Part 11?
The Code of Federal Regulations Title 21 CFR Part 11 (referred to as 21 CFR Part 11) regulates the use of electronic systems in clinical trials. Any pharmaceutical company seeking to submit their clinical trial results to the US Food and Drug Administration (FDA) must first comply with 21 CFR Part 11 as part of their trial and pharmaceutical commercialization process.
This entry discusses what you will need to have in place to make sure the electronic signatures applied by your systems are legally binding.
Electronic Signatures and 21 CFR Part 11
Electronic signatures, as an enabler of automated workflows, can introduce significant efficiencies to the day-to-day operations of your business. To be effective however, electronic signatures need to be applied in manner that conforms to the FDA 21 CFR Part 11 regulations. A full description of the rule on electronic signatures can be found here. While it’s a serious piece of bedtime reading, it does layout the steps you need to take to ensure that the electronic signatures applied within your systems are compliant.
To summarize what it says, the following three points are important to consider:
Procedures and Systems Must Work Together to Achieve 21 CFR Part 11 Compliance
It is important to keep in mind that while a piece of software can enable you to be compliant with 21 CFR Part 11 and its regulation of electronic signatures, it is ultimately your procedures that ensure your compliance. Once both are in place though, any FDA audit that assesses your compliance with 21 CFR Part 11, will become far less onerous.
Electronic signatures are the heartbeat of your online workflow-based system, and the processing efficiencies that are possible by using it properly can lead you to far greater organizational efficiency, growth and profit.